Acquisitions - Summary of Information on Acquisitions to Company's Financial Statements (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	May 06, 2024
Business Acquisition [Line Items]
Initial cash consideration		$ 1,648.8	$ 242.6
Business/technology acquired		$ 307.5	$ 119.5
Nanostring Technologies
Business Acquisition [Line Items]
Acquisition date		May 06, 2024
Initial cash consideration		$ 392.6
Acquired interest		100.00%
Business/technology acquired		$ 90.8		$ 44.7
ELITechGroup
Business Acquisition [Line Items]
Acquisition date		Apr. 30, 2024
Initial cash consideration		$ 951.9
Acquired interest		100.00%
Business/technology acquired		$ 66.9
Chemspeed Technologies A G
Business Acquisition [Line Items]
Acquisition date		Mar. 06, 2024
Initial cash consideration		$ 175.4
Acquired interest		100.00%
Business/technology acquired		$ 106.7
Spectral Instruments Imaging LLC
Business Acquisition [Line Items]
Acquired interest		100.00%
Additional consideration 1		$ 10.0
Additional consideration		$ 10.0
Nion, LLC
Business Acquisition [Line Items]
Acquired interest		100.00%
Additional consideration 1		$ 23.0
Additional consideration		$ 23.0
Biognosys, AG
Business Acquisition [Line Items]
Acquisition date			Jan. 03, 2023
Initial cash consideration			$ 73.6
Acquired interest			97.15%
Remaining ownership percentage under options that can be exercised after acquisition period			2.85%
Business/technology acquired			$ 25.4
PhenomeX Inc [Member]
Business Acquisition [Line Items]
Acquisition date			Oct. 02, 2023
Initial cash consideration	[1]		$ 121.2
Acquired interest			100.00%
Business/technology acquired			$ 74.3

[1] Total cash consideration consisted of $107.2 million for the acquisition of the outstanding stock including an $8.0 million payment to settle an employee award, and settlement of a $14.0 million note previously issued by the Company to PhenomeX during 2023. (b) This amount includes an assumed liability for vested employee awards of $6.3 million on the acquisition date which was settled in the post-closing period ended March 31, 2023, for Biognosys, AG.